BIO CEO McMurry-Heath Steps Down Amid Reported Conflict with Board

Dr. Michelle McMurry-Heath headshot
BIO CEO Dr. Michelle McMurry-Heath has stepped down amid reports of ongoing dissension within the group over its direction.

Biotechnology Innovation Organization (BIO) on Monday announced the resignation of its CEO, molecular immunologist Dr. Michelle McMurry-Heath, after confirming over the weekend that she was on a leave of absence. BIO is the trade association and top lobbying group for

Read More »

Genentech CEO Cites New York Times’ Front Page Story in Appeal for 340B Reforms

Alexander Hardy headshot
Genentech CEO Alexander Hardy cited a recent New York Times investigative article about 340B in an appeal to healthcare leaders to reform the 340B program together.

Genentech CEO Alexander Hardy on Tuesday urged healthcare leaders to reform the 340B program together in the wake of the recent New York Times exposé about a Virginia health system’s alleged misuse of the 340B program.

“As leaders in healthcare,

Read More »

New York Times Investigative Story Aftermath: Leading Local Paper Dives into 340B, Emphasizing its Importance for Community Health Centers

Screengrab of Richmond Times Dispatch, Bon Secours Mercy Richmond Community Hospital article
A Richmond, Va., newspaper ran an Oct. 1 deep dive into 340B's value to health centers in the wake of alleged 340B program misuse by a local health system that has drawn national attention.

In the wake of a recent New York Times investigation into alleged misuse of 340B savings by Catholic health system Bon Secours Mercy in Richmond, Va., a local Richmond newspaper has published a comprehensive look at the purpose and value

Read More »

Fallout from New York Times’s 340B Investigative Piece Continues as Local Media, Policymakers, and Community Weighs In

Screenshot of New York Times Bon Secours Mercy Health hospital article
A New York Times investigative story on the 340B program continues to garner attention both locally and nationally.

Shockwaves from the New York Times’ investigative piece on the alleged misuse of 340B savings by a Catholic health system in Richmond, Virginia continues to spread, as local news outlets and government leaders from all levels respond.  The lengthy article

Read More »

340B HIV Providers Warn of “Drug Industry Disinformation Campaign”

Shannon Stephenson headshot
Drug manufacturers’ true goal is to cripple the 340B program, says Shannon Stephenson, RWC-340B President and CEO of Cempa Community Cares.

Ryan White Clinics for 340B Access (RWC-340B), a national organization of 340B HIV/AIDS medical providers, has published a detailed rebuttal of several recently published articles criticizing the 340B program.  RWC-340B accuses article authors—many of whom are supported by the drug

Read More »

Court Upholds $23 Million Judgement Against CVS Caremark for Unfair Pharmacy Reimbursement

Arcade claw game
CVS Caremark must pay AIDS Healthcare Foundation $23 million for Part D drug reimbursement that the PBM clawed back from AHF unfairly, a court says.

A federal district court in Arizona has upheld a $23 million arbitration award to the AIDS Healthcare Foundation (AHF) against pharmacy benefits manager (PBM) CVS Caremark for unfair drug reimbursement.

In its November 2019 lawsuit, AHF alleged that CVS Caremark

Read More »

340B Provider Groups Decry Federal Judge’s PrEP Coverage Decision

PrEP pill
340B HIV provider groups have condemned a federal court decision that mandating private health insurance coverage of PrEP, a daily medication used to prevent HIV infection, is unconstitutional.

340B HIV provider groups have slammed a recent federal court decision that could have far-reaching implications on access to a host of preventive health care services.

On Sept. 7, Judge Reed O’Connor of the United States District Court for the

Read More »

In Violation of ‘Spirit’ of Anti-Kickback Law, Drug Manufacturer Donations to Patient Assistance Charities Result in Bigger Profits, Study Finds

screenshot of Health Affairs article title
Drug manufacturers' donations to patient assistance charities effectively subsidize the purchase of their own drugs, a new study published in Health Affairs concludes. PhRMA counters that coupons and other forms of assistance help patients afford their out-of-pocket costs.

In a new study published in Health Affairs, researchers find that drug manufacturers are likely to profit from donations they make to patient assistance charities that help patients cover out-of-pocket costs associated with expensive treatments for serious and often rare

Read More »

White House Seeks $27 Billion for COVID-19 and Monkeypox Response

bare arms presenting Monkeypox Mpox rash blisters
The Biden administration is requesting $27 billion to combat monkeypox and COVID-19, but Senate Republicans are signaling skepticism and resistance.

The Biden administration is requesting $27 billion to combat monkeypox and COVID-19 as part of a stopgap spending bill to fund the government past the end of fiscal year 2022, which ends Sept. 30. Senate Republicans are signaling skepticism and

Read More »

GOP House Leaders Want Answers from Becerra on Implementation and Impact of Medicare Drug Price Negotiation

Screenshot of Reps. Kevin Brady, Cathy McMorris Rodgers, and Kevin McCarthy on C-SPAN
Ranking Republicans Kevin Brady (left) and Cathy McMorris Rodgers (center) of House Ways & Means and Energy & Commerce committees sent a letter to HHS foreshadowing intensified oversight if Republicans win back control of the House in November.

Top U.S. House Republicans sent U.S. Health and Human Services Secretary Xavier Becerra a letter on Monday asking 18 detailed questions about implementation and oversight of the Inflation Reduction Act’s (IRA) Medicare drug price negotiation provisions. Their interrogation foreshadows intensified

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

*Sign up for news summaries and alerts from 340B Report